Healthcare
Urologix, Inc.(ULGX)
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- โ
- Revenue Growth
- -14.2%
- EPS Growth
- -71.4%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Urologix, Inc. (ULGX) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of -14.2%, EPS growth of -71.4%, a dividend yield of 0.0%. What stands out right now is revenue -14.2%, EPS -71.4%, free cash flow +22.9% with operating margin -48.7% and ROIC -235.5%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ULGX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-14.2% vs +7.6% peer median
Operating Margin
Below sector median
-48.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2015 was reported on May 12, 2015, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -14.2% and EPS is at -71.4%, with operating margin around -48.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2015 May 12, 2015 | โ | +0.0% | +0.0% | +0.0% |
2015 Feb 5, 2015 | โ | +0.0% | +0.0% | +0.0% |
2014 Nov 4, 2014 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ULGX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
ULGX Max Drawdown
-50.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ULGX and SPY.
Company Overview
Urologix, Inc.
Other OTC
Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota.
- Leadership
- Bryon Merade
- IPO Date
- May 30, 1996
- Employees
- 61
- Street Address
- 14405 21st Avenue North
- Mailing
- Minneapolis, MN, 55447
- Region
- Minneapolis, MN, US
- Reporting Currency
- USD
- Investor Line
- 763 475 1400
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.0
- Price/Book
- โ
Growth
- Revenue
- -14.2%
- EPS
- -71.4%
- Free Cash Flow
- +22.9%
Profitability
- Gross Margin
- 42.8%
- Operating Margin
- -48.7%
- Net Margin
- -53.4%
- ROE
- 232.1%
- ROIC
- -235.5%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.86
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.